Mangalam Drugs Declines 2.07%: 5 Key Events Shaping the Week

2 February 2026: Lower Circuit Amid Heavy Selling Pressure

Mangalam Drugs opened the week on a weak note, hitting its lower circuit limit at Rs.32.68, a 4.97% drop from the previous close. The stock remained locked at this price throughout the session, reflecting intense selling pressure and a lack of buying interest. Trading volumes were subdued at 0.177 lakh shares, with turnover of just ₹0.058 crore. This sharp decline contrasted with a modest 0.22% gain in the Sensex and a 0.24% dip in the Pharmaceuticals & Biotechnology sector, highlighting company-specific challenges. The stock’s persistent downtrend, having lost nearly 37% over nine sessions, was exacerbated by weak investor participation and technical indicators signalling bearish momentum.

3 February 2026: Upper Circuit Triggered on Robust Buying

In a dramatic reversal, Mangalam Drugs surged 5.00% to Rs.38.01, hitting the upper circuit limit and closing at this peak. The stock outperformed the Pharmaceuticals & Drugs sector gain of 2.81% and the Sensex’s 2.56% rise, buoyed by strong investor demand and a surge in delivery volumes to 4.34 lakh shares. Turnover jumped to ₹1.64 crore, signalling renewed buying interest. Despite this short-term strength, the stock remained below most longer-term moving averages, indicating resistance ahead. The upper circuit freeze reflected unfilled buy orders and heightened investor conviction, though the company’s fundamental mojo grade remained a bearish 9.0 (Strong Sell).

4 February 2026: Return to Lower Circuit on Heavy Selling

The stock reversed sharply, plunging 4.99% to close at Rs.36.01, again hitting the lower circuit limit. Despite the broader Pharmaceuticals & Biotechnology sector gaining 0.30% and the Sensex rising 0.16%, Mangalam Drugs faced intense selling pressure. Trading volume increased to 1.38 lakh shares with a turnover of ₹0.50 crore, but the weighted average price was near the day’s low, indicating sustained bearish sentiment. The stock’s technical position remained weak, trading below most moving averages except the 50-day. The downgrade to a Strong Sell mojo grade and deteriorating fundamentals contributed to the negative outlook and investor caution.

5 February 2026: Consecutive Lower Circuit Close Amid Panic Selling

Mangalam Drugs continued its downward spiral, closing at Rs.34.21 after hitting the lower circuit limit with a 5.0% loss. The stock remained locked at this price throughout the session, with volume at 0.294 lakh shares and turnover of ₹0.10 crore. Delivery volumes fell sharply by 54.78%, signalling retreat by long-term holders. The stock underperformed its sector, which declined 0.75%, and the Sensex, which fell 0.47%. Technical indicators showed a clear negative trend with a cumulative 9.74% loss over two days. The micro-cap’s limited liquidity and strong sell mojo rating intensified volatility and selling pressure.

6 February 2026: Week Ends with Lower Circuit Amid Sustained Downtrend

The week closed with Mangalam Drugs hitting the lower circuit limit once more, falling 5.0% to Rs.32.50. The stock opened down 3.51% and slid steadily, with volume rising to 1.886 lakh shares and turnover of ₹0.62 crore. Most trades occurred near the day’s low, indicative of panic selling and sharply reduced investor confidence. The stock traded below all key moving averages, reflecting broad technical weakness. Over the last three sessions, the stock declined 14.25%, significantly underperforming the sector and Sensex. Delivery volumes dropped 87.67%, highlighting waning long-term investor interest. The micro-cap status and strong sell mojo grade reinforce the bearish outlook and elevated risk profile.

Key Takeaways

The week for Mangalam Drugs was marked by extreme volatility, with three lower circuit hits and one upper circuit event. The stock’s 2.07% weekly decline contrasts sharply with the Sensex’s 1.51% gain, highlighting company-specific challenges. Heavy selling pressure, panic selling, and sharply reduced delivery volumes indicate deteriorating investor confidence and fundamental concerns. Despite brief bouts of strong buying interest, technical indicators remain weak, with the stock trading below most moving averages. The micro-cap status and a Strong Sell mojo grade of 9.0 further underscore the elevated risk and limited liquidity. Investors should note the persistent downtrend and cautious market sentiment prevailing throughout the week.

Conclusion

Mangalam Drugs and Organics Ltd’s week was dominated by sharp swings and circuit breaker events, reflecting a fragile technical and fundamental position. The stock’s inability to sustain gains and repeated lower circuit hits amid a stable sector and market backdrop point to company-specific headwinds. The strong sell mojo rating and micro-cap volatility compound the risks, suggesting that the stock remains vulnerable to further downside. Market participants should closely monitor upcoming corporate developments and sector trends for any signs of stabilisation. Until then, the prevailing sentiment and price action warrant a cautious stance towards this stock.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →